Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Press Releases

13 Press Releases
DateTitleCompany
10 May 12 ThromboGenics NV - Business Update ThromboGenics NV,
Published by
PR Newswire
17 Apr 12 ThromboGenics Resubmits BLA for Ocriplasmin with the FDA ThromboGenics NV
24 Feb 12 ThromboGenics to Present at the Citi 2012 Global Health Care Conference in New York ThromboGenics NV,
Published by
PR Newswire
05 Nov 10 ThromboGenics NV – Business Update ThromboGenics NV,
Published by
PharmiWeb.com
17 May 10 ThromboGenics and BioInvent to Receive EUR10 Million Milestone as Partner Roche Begins New Clinical Study with TB-403 ThromboGenics NV,
Published by
PR Newswire
06 May 10 ThromboGenics and BioInvent Announce Positive Topline Results From Phase II VTE Prophylaxis Study With Anti-Factor VIII (TB-402) ThromboGenics NV,
Published by
PR Newswire
20 Apr 10 ThromboGenics Announces that Microplasmin Meets Primary Endpoint in Phase III Trial for the Non-Surgical Treatment of Symptomatic Vitreomacular Adhesion (VMA) ThromboGenics NV,
Published by
PR Newswire
16 Dec 09 ThromboGenics Completes Patient Enrolment of Second Phase III Trial of Microplasmin for the Non-Surgical Treatment of Eye Disease ThromboGenics NV,
Published by
PR Newswire
17 Nov 09 ThromboGenics and BioInvent Complete Phase I Patient Trial of Anti-PlGF Cancer Therapeutic TB-403 in Patients With Advanced Solid Tumours ThromboGenics NV,
Published by
PR Newswire
13 Mar 09 ThromboGenics Announces Business Update and 2008 Full Year Results ThromboGenics NV
09 Mar 09 ThromboGenics Completes Patient Enrolment for Phase II Trial of Microplasmin for the Treatment of Diabetic Macular Edema (MIVI II DME) ThromboGenics NV
27 Feb 09 ThromboGenics Awarded €3.2 Million Grant for the Development of its Anti-VPAC1 Antibody for Cancer Chemotherapy Induced Thrombocytopenia ThromboGenics NV
26 Jan 09 ThromboGenics and BioInvent Receive Technology Transfer Success Fee from Roche for the Novel Anti-Cancer Antibody, TB-403 (Anti-PIGF) ThromboGenics NV /BioInvent International AB
Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.